卡铂+依托泊苷(Vp-16)即CE方案常作为肺癌的一线化疗方案。国内有关CE方案对肝功能影响的报告较少。今将1990年～1992年期间我院的肺癌患者在使用CE方案化疗后出现肝功能损害的情况,报告如下: 1 临床资料:接受CE方案的22例肺癌患者均经病理学或细胞学诊断证实。男18例,女4例,平均年龄57.3岁,小细胞肺癌(SCLC)7例,非小细胞肺癌(NSCLC)15例,分别有纵隔、肺门淋巴结及其他部位的转移,但均无肝脏转移(腹部 Carboplatin + etoposide (Vp-16) that the CE program often used as first-line chemotherapy for lung cancer. Domestic reports on the impact of CE program less on liver function. This will be from 1990 to 1992 in our hospital lung cancer patients after using the CE regimen of liver damage, the report is as follows: 1 Clinical data: 22 cases of lung cancer patients undergoing CE regimen were confirmed by pathological or cytological diagnosis . There were 18 males and 4 females, with an average age of 57.3 years. There were 7 cases of small cell lung cancer (SCLC) and 15 cases of non-small cell lung cancer (NSCLC) with mediastinal, hilar lymph nodes and other metastases, (abdomen